Physician profile
Charles E Moore
NPI 1275687493
$7,029.81
in general payments reported to CMS, 2019-2025
28 companies · $593 in 2025
The $593 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,519 · 2020: $1,156 · 2021: $2,047 · 2022: $585 · 2023: $688 · 2024: $441 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,721.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,431.97 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $1,244.76 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Sanofi-Aventis U.S. LLC | $883.85 | 2019-2023 | |
| Novo Nordisk INC | $799.62 | 2019-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $481.20 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $317.94 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $296.47 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $232.88 | 2019-2021 | |
| Amgen INC. | $204.07 | 2024-2025 | Krystexxa |
| Arbor Pharmaceuticals, INC. | $144.71 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.50 | 2019-2023 | Jardiance |
| Pfizer INC. | $137.52 | 2019-2025 | |
| Allergan, INC. | $135.78 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $91.05 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Merck Sharp & Dohme LLC | $79.33 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $74.59 | 2019-2020 | |
| Horizon Therapeutics Plc | $62.85 | 2023 | Krystexxa |
| Glaxosmithkline, LLC. | $56.16 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.26 | 2024-2025 | Caplyta |
| Abbott Laboratories | $29.17 | 2024 | Freestyle Libre 3 |
| Exact Sciences Corporation | $21.91 | 2023 | Cologuard Collection Kit |
| Ibsa Pharma INC. | $21.24 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $20.16 | 2022 | |
| Medtronic USA, INC. | $18.17 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.00 | 2024 | Xifaxan |
| Dexcom, INC. | $16.45 | 2019 | |
| Azurity Pharmaceuticals, INC. | $15.21 | 2023 | Edarbi |
| Biohaven Pharmaceuticals, INC. | $11.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.